Survival time according to the year of recurrence and subtype in recurrent breast cancer.
CONCLUSION: Our study revealed that the survival rate of patients with only the HER2-enriched subtype significantly improved after recurrence. To prolong the survival time after recurrence of both luminal and triple negative subtypes, the development of novel targeting therapies to overcome refractory recurrent breast cancer is extremely important. PMID: 26099804 [PubMed - as supplied by publisher]
Authors: Gomes I, de Almeida BP, Dâmaso S, Mansinho A, Correia I, Henriques S, Cruz-Duarte R, Vilhais G, Félix P, Alves P, Corredeira P, Barbosa-Morais NL, Costa L, Casimiro S Abstract The role of RANKL-RANK pathway in progesterone-driven mammary carcinogenesis and triple negative breast cancer tumorigenesis has been well characterized. However, and despite evidences of the existence of RANK-positive hormone receptor (HR)-positive breast tumors, the implication of RANK expression in HR-positive breast cancers has not been addressed before. Here, we report that RANK pathway affects the expression of cel...
British Journal of Cancer, Published online: 03 June 2020; doi:10.1038/s41416-020-0909-4Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes—a Hellenic Cooperative Oncology Group (HeCOG) Trial
Publication date: June 2020Source: European Journal of Surgical Oncology, Volume 46, Issue 6Author(s): Amber Shivarajan, Hiba Fatayer, Nicholas Hobbs, Sami Titi, Nabila Nasir
In HER2-positive breast cancer patients with brain metastases treated with trastuzumab and capecitabine, tucatinib increased median overall survival from 12 months to 18.1 months in a phase 2 trial.Medscape Medical News
Contributors : Liu Yuan ; Zhu ZhouSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensA large-panel gene expression analysis was conducted to identify biomarkers associated with the effectiveness of adding palbociclib to letrozoleCyclin-dependent kinase 4/6 (CDK4/6) inhibitors have demonstrated significant activity in estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer. Further biomarkers to refine the population beyond ER+/HER2- that benefits remain to be identified. We performed a comprehensive biomarker analysis using patient ...
Condition: Metastatic Breast Cancer Intervention: Drug: Pyrotinib Maleate plus Letrozole Sponsors: Hunan Cancer Hospital; Jiangsu HengRui Medicine Co., Ltd. Recruiting
British Journal of Cancer, Published online: 29 May 2020; doi:10.1038/s41416-020-0908-5Correction: Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007–2016)
In this study, we aimed to identify novel lncRNAs that might play critical roles in doxorubicn resistance, which could reveal potential biomarkers of BC. Using a BC dataset (GSE81971), we identified 452 lncRNAs that were upregulated and 659 that were downregulated; furthermore, there were 1896 differentially expressed mRNAs, of which 1137 were upregulated and 758 were downregulated in MCF-7/ADR cells compared with the expression in MCF-7 cells. We constructed an lncRNA–mRNA network by integrating probe reannotation and regulatory interactions. To elucidate the key lncRNAs in BC, we further analyzed dysregulated lncRN...
CONCLUSION: The ppStage reflects the prognosis of patients with early breast cancer more accurately than the aStage. PMID: 32472474 [PubMed - as supplied by publisher]
CONCLUSION: Our findings of overexpression of LAT1 in negative HER2 group suggest a role of this protein as prognosticator and drug target in a challenging therapeutic cohort.. PMID: 32458655 [PubMed - in process]